HGH

Ericson (2010) examined cancer risk in GH-deficient adults treated with recombinant human growth hormone. The study followed 6,000+ patients over 15+ years with profoundly elevated GH and IGF-1 levels (higher than any peptide would produce). Result: zero increased cancer incidence, actually slightly lower than age-matched controls. Additionally, a 2018 Stockholm study published in JAMA followed GH-deficient patients in Denmark and Sweden for 30+ years and found slightly lower cancer risk in treated patients.

Dr. Bachmeyer strongly advises against exogenous HGH for 99.9% of people, stating it is 'riddled with side effects' and 'causes catastrophic problems with your pituitary.' He distinguishes HGH from GH analogs (CJC-1295, Tesamorelin, Ipamorelin), recommending the analogs instead unless HGH is medically necessary.